Cargando…
Proteasome Inhibition Is Partially Effective in Attenuating Pre-Existing Immunity against Recombinant Adeno-Associated Viral Vectors
Pre-existing immunity against adeno-associated virus (AAV) remains a major challenge facing the clinical use of systemic administration of recombinant AAV vectors for the treatment of genetic and acquired diseases using gene therapy. In this study, we evaluated the potential of bortezomib (marketed...
Autores principales: | Karman, Jozsef, Gumlaw, Nathan K., Zhang, Jinhua, Jiang, Ji-Lei, Cheng, Seng H., Zhu, Yunxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326043/ https://www.ncbi.nlm.nih.gov/pubmed/22514654 http://dx.doi.org/10.1371/journal.pone.0034684 |
Ejemplares similares
-
A Bispecific Protein Capable of Engaging CTLA-4 and MHCII Protects Non-Obese Diabetic Mice from Autoimmune Diabetes
por: Zhao, Hongmei, et al.
Publicado: (2013) -
Production and Titering of Recombinant Adeno-associated Viral Vectors
por: McClure, Christina, et al.
Publicado: (2011) -
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
por: Clément, Nathalie, et al.
Publicado: (2016) -
Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome
por: Ayuso, Eduard
Publicado: (2016) -
Strong ubiquitous micro-promoters for recombinant adeno-associated viral vectors
por: Chai, Sunghee, et al.
Publicado: (2023)